# The British Journal of Clinical Pharmacology

Volume 44
1997

Published for
The British Pharmacological Society by
Blackwell Science

© 1997 Blackwell Science Ltd
Osney Mead, Oxford OX2 0EL
25 John Street, London WC1N 2BL
23 Ainslie Place, Edinburgh EH3 6AJ
Commerce Place, 350 Main Street, Malden MA 02148-5018, USA
54 University Street, Carlton, Victoria 3053, Australia

Other Editorial Offices:
Blackwell Wissenschafts-Verlag GmbH
Kurfürstendamm 57
1707 Berlin
Germany

Blackwell Science KK
MG Kodenmacho Building
7–10 Kodenmacho Nihombashi
Chuo-ku, Tokyo 104
Japan

Published on behalf of
The British Pharmacological Society

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the copyright owner. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Blackwell Science for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the base fee of $14.00 per copy is paid directly to CCC, 222 Rosewood Drive, Suite 910, Danvers, MA 01923, USA. 0206-5251/97 $14.00/0. (For copying beyond that permitted by Sections 107 or 108 of the US Copyright Law). This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Special requests should be addressed to the Editor.

Typeset by The Charlesworth Group, Huddersfield
Printed in Great Britain
at the University Press, Cambridge

# Contents

## Volume 44, Number 1, July 1997


**Review**

1 Antimalarial drugs and glucose metabolism: *T. M. E. Davis*

**SmithKline Beecham Prize Lecture**

9 Endothelin: from molecule to man: *D.J. Webb*

**Pharmacokinetics and drug disposition**

21 The mechanism of the carbamazepine-valproate interaction in humans: *I. Bernus, R.G. Dickinson, W.D. Hooper and M.J. Eadie*

29 Regional metabolism of articaine in 10 patients undergoing intravenous regional anaesthesia during day case surgery: *T.B. Vree, M.A.M. Simon, M.J.M. Gielen and L.H.D.J. Booij*

**Pharmacokinetics and drug pharmacodynamics**

35 Improved bioavailability and clinical response in patients with chronic liver disease following the administration of a spironolactone: β-cyclodextrin complex: *A.Z.M. Abosehmah-Albidy, P. York, V. Wong, M.S. Losowsky and H. Chrystyn*

41 Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics: *J. Dingemanse, C.H. Kleinbloesem, G. Zürcher, N.D. Wood and C. Crevoisier*

**Pharmacodynamics**

49 The comparison of the responsiveness of human isolated internal mammary and gastroepiploic arteries to levcromakalim: an alternative approach to the management of graft spasm: *F. Akar, B. Sönmez Uydeş-Doğan, H. Tufan, S. Aşlamaci, C. Köksoy and İ. Kanzik*

57 Haemodynamic effects of adrenomedullin in human resistance and capacitance vessels: *J.R. Cockcroft, J.P. Noon, J. Gardner-Medwin and T. Bennett*

61 Bisoprolol attenuates noradrenaline- and phenylephrine-evoked venoconstriction in man *in vivo*: *A.H. Abdelmawla, R.W. Langley, E. Szabadi and C.M. Bradshaw*

69 Further evidence that chronic perindopril treatment maintains neurohormonal suppression but does not lower blood pressure in chronic cardiac failure: *R.J. MacFadyen, C.S. Barr, N.D.C. Sturrock, M. Fenwick and A.D. Struthers*

77 Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets: *H. Osamah, R. Mira, S. Sorina, K. Shlomo and A. Michael*

**Therapeutics**

85 Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects. Results of a case-control study: *D. Henry, J. Page, I. Whyte, R. Nanra and C. Hall*

**Short reports**

91 Single-dose pharmacokinetics of felbamate in patients with renal dysfunction: *P. Glue, W. Sulowicz, R. Colucci, C. Banfield, S. Pai, C. Lin and M.B. Affrime*

94 The effect of pharmacological supplementation with vitamin C on low-density lipoprotein oxidation: *Y. Wen, T. Cooke and J. Feely*

98 Reporting of adverse drug reactions by hospital doctors and the response to intervention: *P. McGettigan, J. Golden, R. M. Conroy, N. Arthur and J. Feely*

101 Clinical Pharmacology and Therapeutics—past, present and future: *J.L. Reid*

**Letter to the Editors**

105 Spontaneous reports of psychiatric adverse effects to mefloquine in the Netherlands: *M.M. van Riemsdijk, M.M. van der Klauw, L. Pepplinkhuizen and B.H. Ch. Stricker*


## Volume 44, Number 2, August 1997


**Leading articles**

107 Education in Clinical Pharmacology and Therapeutics in a changing world *M. Orme*

109 Pharmacovigilance in the 1990s *D.H. Lawson*

**Review**

111 β-adrenoceptor blockers in chronic heart failure–a review *H. Krum*

**Pharmacokinetics and drug disposition**

119 Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose *U. Hellgren, I. Berggren-Palme, Y. Bergqvist and M. Jerling*

125 Cyclosporin pharmacokinetics following administration of capsules and Neoral in paediatric patients with lupus nephritis *L.W. Fu, L.Y. Yang, W.P. Chen and C.Y. Lin*

129 Single and multiple dose pharmacokinetics of felbamate in the elderly *A. Richens, C.R. Banfield, M. Salfi, A. Nomeir, C.C. Lin, P. Jensen, M.B. Affrime and P. Glue*

135 Pharmacokinetics of digoxin-specific Fab: effects of decreased renal function and age *C. Renard, N. Grene-Lerouge, N. Beau, F. Baud and J.M. Schermann*

**Pharmacokinetics and pharmacodynamics**

139 The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis *M.M. van Miert, N.B. Eastwood, A.H. Boyd, C.J.R. Parker and J.M. Hunter*

**Pharmacodynamics**

145 Do trandolapril and indomethacin influence renal function and renal functional reserve in hypertensive patients? *G. Pritchard, D. Lyons, J. Webster, J.C. Petrie and T.M. MacDonald*

151 A comparison of the effects of aspirin on bleeding time measured using the Simplate® method and closure time measured using the PFA-100®, in healthy volunteers *P.W. Marshall, A.J. Williams, R.M. Dixon, J.W. Growcott, S. Warburton, J. Armstrong and J. Moores*

**Therapeutics**

157 Chloroquine-induced pruritus in malaria fever: contribution of malaria parasitaemia and the effects of prednisolone, niacin, and their combination, compared with antihistamine *R.A. Adebayo, G.G. Sofowora, O. Onayemi, S.J. Udoh and A.A. Ajayi*

163 An investigation of hospital generated pharmaceutical care when patients are discharged home from hospital *L. Smith, L. McGowan, C. Moss-Barclay, J. Wheater, D. Knass and H. Chrystyn*

**Education**

167 Developing a core curriculum in clinical pharmacology and therapeutics: a Delphi study *T. Walley and D.J. Webb*

171 Core content of a course in Clinical Pharmacology *T. Walley and D.J. Webb*

**Pharmacovigilance**

175 Omeprazole, other antiulcer drugs and newly diagnosed gout *C.R. Meier and H. Jick*

179 Is metronidazole teratogenic? A meta-analysis *T. Caro-Patón, A. Carvajal, I. Martín de Diego, L.H. Martín-Arias, A. Alvarez Requejo and E. Rodríguez Pinilla*

**Short reports**

183 Pharmacokinetics of the S(+) and R(−) enantiomers of vigabatrin during chronic dosing in a patient with renal failure *E. Jacqz-Aigrain, M. Guillonneau, E. Rey, M.-A. Macher, C. Montes, C. Chiron and C. Loirat*

186 Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19 *L. Bertilsson, G. Tybring, J. Widén, M. Chang and T. Tomson*

190 Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir *V.A. Eagling, D.J. Back and M.G. Barry*

195 Effect of troleandomycin on the pharmacokinetics of imipramine in Chinese: the role of CYP3A *Jun-Sheng Wang, Wei Wang, Hong-Guang Xie, Song-Lin Huang and Hong-Hao Zhou*

199 Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin *M. Priskorn, J.S. Sidhu, F. Larsen, J.D. Davis, A.Z. Khan and P.E. Rolan*

203 Erythropoietin production in healthy volunteers subjected to controlled hypobaric hypoxia: further evidence against a role for adenosine *C.H. Gleiter, T. Becker and J. Wenzel*

206 The effect of age on plasma MEGX concentrations *R. Orlando and P. Palatini*

**Letters to the Editors**

209 Captopril has no significant scavenging antioxidant activity in human plasma *in vitro* or *in vivo* *I.F.F. Benzie, B. Tomlinson, J.A.J.H. Critchley, D. Lapenna and F. Cuccurullo*

210 Fluvoxamine in breast-milk and infant development *K. Yoshida, B. Smith and R. Channi Kumar*

211 Ibuprofen in human milk *K. Walter and C. Dilger*

213 Pharmacokinetics of inhaled drugs *S. Vozeh and B. Lipworth*

## Volume 44, Number 3, September 1997

**Leading article**

215 The Clinical Section of the British Pharmacological Society: prospects for the future *N.S. Baber, G.T. Tucker and D.J. Webb*

**Review**

219 The contribution of clinical pharmacology surrogates and models to drug development—a critical appraisal *P. Rolan*

**Lilly Prize Lecture**

227 'Keep on taking the tablets': pharmacological adaptation during long-term drug therapy *D.G. Grahame-Smith*

**Pharmacokinetics and drug disposition**

239 Indices and graphical approaches for the detection of interindividual and interethnic variations in codeine metabolism *Q.Y. Yue, L. Iselius and J. Säwe*

245 The effect of omeprazole on the pharmacokinetics of metronidazole and hydroxymetronidazole in human plasma, saliva and gastric juice *M.J. Jessa, A.F. Goddard, D.A. Barrett, P.N. Shaw and R.C. Spiller*

255 Non-linear pharmacokinetics of high-dose intravenous verapamil *G. Toffoli, I. Robieux, D. Fantin, M. Gigante, S. Frustaci, G.L. Nicolosi, M. De Cicco and M. Boiocchi*

261 Predictive performance of renal function estimate equations in renal allografts *P.J. Goerdt, K.L. Heim-Duthoy, M. Macres and S.K. Swan*

**Pharmacodynamics**

267 A study of the effects of long-term use on individual sensitivity to temazepam and lorazepam in a clinical population *A.L. van Steveninck, A.E. Wallnöfer, R.C. Schoemaker, M.S.M. Pieters, M. Danhof, J.M.A. van Gerven and A.F. Cohen*

**Pharmacovigilance**

277 Non-puerperal lactation associated with antidepressant drug use *A.C.G. Egberts, R.H.B. Meyboom, F.H.P. de Koning, A. Bakker and H.G.M. Leufkens*

**Short reports**

283 Effect of melatonin and metabolites on copper-mediated oxidation of low density lipoprotein *H. Seeger, A.O. Mueck and T.H. Lippert*

285 Bradykinin-induced venodilation is not different in blacks *Z. Vajo, M. McDonald, B. Takahashi, H. Zafar, K. Srivathsan & W.D. Dachman*

289 Evening dosing is associated with higher plasma concentrations of pranlukast, a leukotriene receptor antagonist, in healthy male volunteers *D.R. Brocks, J. Upward, M. Davy, K. Howland, C. Compton, C. McHugh and M.J. Dennis*

292 Forearm endothelium-dependent vascular responses and the potassium-ATP channel *D. McAuley, C. McGurk, A.G. Nugent, C. Hanratty, S. Maguire and G.D. Johnston*

295 Excretion of citalopram in breast milk *O. Spigset, L. Carleborg, R. Öhman and Å. Norström*

299 Temporal trends in spontaneous reporting of unlabelled adverse drug reactions *F. Haramburu, B. Bégaud and Y. Moride*

**Letters to the Editors**

303 A genetic bias in clinical trials? Cytochrome P450-2D6 (CYP2D6) genotype in general *vs* selected healthy subject populations *S. Chen, S. Kumar, W.-H. Chou, J.S. Barrett and P.J. Wedlund*

304 Medroxyprogesterone acetate induced Cushing's syndrome *K. Shotliff and S.S. Nussey*

305 Bioavailability of artemether *G.O. Kokwaro*

**Book review**

306 Lecture Notes on Clinical Pharmacology—5th edition *J.L. Reid, P.C. Rubin and B. Whiting: D. Waller*

# Volume 44, Number 4, October 1997


**Reviews**

307 Free radicals and antioxidants in cardiovascular disease: *S.R.J. Maxwell and G.Y.H. Lip*

319 Lipoproteins and cardiovascular reactivity: *L.G. Howes, D. Abbott and N.E. Straznicky*

**Pharmacokinetics and drug disposition**

325 The pharmacokinetics of methadone in healthy subjects and opiate users: *K. Wolff, L. Rostami-Hodjegan, S. Shires, A.W.M. Hay, M. Feely, R. Calvert, D. Raistrick and G.T. Tucker*

335 Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency: *F.O. Müller, J. Terblanchè, R. Schall, R. van Zyl Smit, T. Tucker, K. Marais, G. Groenewoud, H.C. Porchet, M. Weincr and D. Hawarden*

343 Decreased oral availability of cyclosporin A at second administration in humans: *Y.J. Lee, S.J. Chung and C.K. Shim*

347 Relative dispersion of intravascular transit times during isolated human limb perfusions for recurrent melanoma: *M.S. Roberts, Z.Y. Wu, L.P. Rivory, B.M. Smithers, W.S. Egerton and M. Weiss*

**Pharmacodynamics**

353 Inhibition of vasoconstriction by potassium channel opener aprikalim in human conduit arteries used as bypass grafts: *G.-W. He and C.-Q. Yang*

361 Comparison of nitroprusside and nitroglycerin in inhibition of angiotensin II and other vasoconstrictor-mediated contraction in human coronary bypass conduits: *G.-W. He and C.-Q. Yang*

369 Effects of losartan on cerebral and ocular circulation in healthy subjects: *B. Matulla, G. Streit, S. Pieh, O. Findl, J. Entlicher, U. Graseli, H.G. Eichler, M. Wolzt and L. Schmetterer*

377 The peptide endothelin receptor antagonist, TAK-044 produces sustained inhibition of endothelin-1 mediated arteriolar vasoconstriction: *C.J. Ferro, W.G. Haynes, N.R. Johnston, C.C. Lomax, D.E. Newby and D.J. Webb*

385 Influence of SNN-6010, an elemental diet, on the generation of cytokines, NO, and chemiluminescence from leukocytes and umbilical vein endothelial cells in man: *E. Ueta, K. Yoneda, T. Yamamoto and T. Osaki*

**Drug interactions**

393 An evaluation of the interaction of meloxicam with frusemide in patients with compensated chronic cardiac failure: *F.O. Müller, M.V. Middle, R. Schall, J. Terblanché, H.K.L. Hundt and G. Groenewoud*

399 No effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamics: *J.N.J.M. de Hoon, H.H.W. Thijssen, A.J.M.M. Beysens and L.M.A.B. Van Bortel*

403 Effects of tedisamil, atenolol and their combination on heart and rate-dependent QT interval in healthy volunteers: *J.L. Dèmolis, C. Martel, C. Funck-Brentano, A. Sachse, H.J. Weimann and P. Jaillon*

**Letters to the Editors**

411 Brodimoprim: adverse drug reactions from spontaneous reporting: *A. Conforti, L. Gugliemo, L. Naldi, A. Cocci, M. Venegoni and R. Leone*

412 Aminophylline and essential tremor: *J. Málly*


# Volume 44, Number 5, November 1997


**Leading article**

413 Can drug delivery systems deliver value in the new pharmaceutical marketplace?: *J.Urquhart*

**Reviews**

421 Economic evaluation of pharmaceuticals: what are reasonable standards for clinical evidence – the Australian experience: *S. Hill, D. Henry, B. Perkarsky and A. Mitchell*

427 Drug treatment in acute porphyria: *A. Gorchein*

**Opinion**

435 Homoeopathy: past, present and future: *E. Ernst*

**Pharmacokinetics and drug disposition**

439 The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine: *B. Eiermann, G. Engel, I. Johansson, U. M. Zanger and K. Bertilsson*

447 Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method: *M. Jerling, Y. Merlé, F. Mentré and A. Mallet*

455 Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity: *L. Lennard, J. C. Welch and J. S. Lilleyman*

**Pharmacodynamics**

463 Tolerance to the repolarization effects of *rac*-sotalol during long-term treatment: *R. Padrini, M. Gusella, M. Al Bunni, D. Piovan, R. Zordan, G. Magnolfi, P. Maiolino and M. Ferrari*

471 Effects of prostacyclin on renal haemodynamics, renal tubular function and vasoactive hormones in healthy humans. A placebo-controlled dose-response study: *C. B. Nielsen, J. N. Bech and E. B. Pedersen*

**Pharmacokinetics and Pharmacodynamics**

477 Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects: *J. Dingemanse, J. M. A. van Gerven, R. C. Schoemaker, G. Roncari, J. J. L. Oberyé, M. F. van Oostenbruggen, J. Massarella, P. Segala, M. Zell and A. F. Cohen*

487 Integrated pharmacokinetics and pharmacodynamics of Ro 48-8684 a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects: *J. M. A van Gerven, G. Roncari, R. C. Schoemaker, J. Massarella, P. Keesmaat, H. Kooyman, P. Heizmann, M. Zell, A. F. Cohen and J. Dingemanse*

**Drug interactions**

495 Inhibition of CYP2C9 by selective serotonin reuptake inhibitors *in vitro*: studies of phenytoin *p*-hydroxylation: *J. Schmider, D. J. Greenblatt, L. L. von Moltke, D. Karsov and R. I. Shader*

499 Diltiazem-cyclosporin pharmacokinetic interaction–dose-response relationship: *T. E. Jones, R. G. Morris and T. H. Mathew*

505 Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes: *X.-J. Zhao and T. Ishizaki*

**Short report**

513 Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database: *N. Moore, C. Kreft-Jais, F. Haramburu, C. Noblet, M. Andrejak, M. Ollagnier and B. Bégaud*

**Book reviews**

519 Fundamentals of Psychopharmacology: *R. Kerwin*

519 Principles of Neuropsychopharmacology: *L. Iversen*

## Volume 44, Number 6, December 1997

**Pharmacokinetics and drug disposition**

521 Effect of high-fat, high-protein, and high-carbohydrate meals on the pharmacokinetics of a small dose of ethanol: *A. W. Jones, K. Å. Jönsson and S. Kechagias*

527 Effect of buffering on pharmacokinetics of ketoprofen enantiomers in man: *H. Fuder, S. Stiegler, N. Wetzelsberger, G. Wieckhorst, R. Lange and P. W. Lücker*

531 Pharmacokinetics of temocapril and temocaprilat after 14 once daily oral doses of temocapril in hypertensive patients with varying degrees of renal impairment: *K. Püchler, K. M. Eckl, L. Fritsche, K. Renneisen, H.-H. Neumayer, B. Sierakowski, A. T. J. Lavrijssen, T. Thomsen and I. Roots*

537 Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients: *F. Akhlaghi, A. J. McLachlan, A. M. Keogh and K. F. Brown*

543 Methadone distribution and excretion into breast milk of clients in a methadone maintenance programme: *R. E. Wojnar-Horton, J. H. Kristensen, P. Yapp, K. F. Ilett, L. J. Dusci and L. P. Hackett*

549 Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine: *L. C. Kirkwood, R. L. Nation and A. A. Somogyi*

557 Characterization of the cytochrome P450 isoenzymes involved in the *in vitro* *N*-dealkylation of haloperidol: *L. P. Pan, P. Wijnant, C. De Vriendt, M. T. Rosseel and F. M. Belpaire*

**Pharmacodynamics**

565 Effects of oral and inhaled corticosteroid on lymphocyte $\beta_2$-adrenoceptor function in asthmatic patients: *K. S. Tan, L. C. McFarlane and B. J. Lipworth*

569 Dose- and time-dependency of the dilator effects of the endothelin antagonist, BQ-123, in the human forearm: *J. R. Berrazueta, K. Bhagat, P. Vallance and R. J. MacAllister*

573 Benazepril, an angiotensin converting enzyme inhibitor: drug interaction with salbutamol and bronchial response to histamine in normal subjects: *K. G. Bauer, P. Brunel, G. Nell, G. Quinn and G. A. Kaik*

**Pharmacovigilance**

577 A prescription survey in a hospital hypertension outpatient clinic: *P. K. F. Lee, R. K. L. Li, J. C. N. Chan, S. Chang, S. C. Lee, B. Tomlinson and J. A. J. H. Critchley*

**Clinical trials**

583 Clinical trials and clinical practice: do doctors use the same criteria to judge outcome?: *D. M. Chaput de Saintonge, S. J. W. Evans, G. J. Crane and J. R. Kirwan*

**Short reports**

587 Transplacental distribution of salbutamol enantiomers at caesarian section: *D. W. Boulton, J. P. Fawcett and T. M. Fiddes*

591 Trimetazidine does not modify blood levels and immunosuppressant effects of cyclosporine A in renal allograft recipients: *N. Simon, P. Brunet, D. Roumenov, B. Dussol, J. Barre, J.-C. Duche, E. Albengres, P. D'Athis, A.-M. Chauvet-Monges, Y. Berland and J.-P. Tillement*

595 The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90): *R. W. Peck, E. J. Seaber, R. Dixon, C. G. Gillotin, B. C. Weatherley, G. Layton and J. Posner*

601 Indexes to Volume 44